266 related articles for article (PubMed ID: 15915153)
1. Measuring the value of pharmacogenomics.
Phillips KA; Van Bebber SL
Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153
[TBL] [Abstract][Full Text] [Related]
2. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
3. Evolution of pharmacogenomics.
Somogy A
Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
[TBL] [Abstract][Full Text] [Related]
4. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
5. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
Lesko LJ; Woodcock J
Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics: bench to bedside.
Weinshilboum R; Wang L
Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
[TBL] [Abstract][Full Text] [Related]
7. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
Mandry T
Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Arranz MJ; de Leon J
Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
[TBL] [Abstract][Full Text] [Related]
9. Economic opportunities and challenges for pharmacogenomics.
Deverka PA; Vernon J; McLeod HL
Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy.
Pappas DJ; Oksenberg JR
Neurology; 2010 Jan; 74 Suppl 1():S62-9. PubMed ID: 20038765
[TBL] [Abstract][Full Text] [Related]
11. A pharmacogenomics primer.
Court MH
J Clin Pharmacol; 2007 Sep; 47(9):1087-103. PubMed ID: 17664254
[TBL] [Abstract][Full Text] [Related]
12. Assessing patient readiness for the clinical adoption of personalized medicine.
Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics - therapeutic and ethical issues.
Patowary S
Kathmandu Univ Med J (KUMJ); 2005; 3(4):428-30. PubMed ID: 16449851
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic discovery approaches: will the real genes please stand up?
Walgren RA; Meucci MA; McLeod HL
J Clin Oncol; 2005 Oct; 23(29):7342-9. PubMed ID: 16145062
[TBL] [Abstract][Full Text] [Related]
15. The DNA Rx. Advances in genetics give physicians ability to tailor drugs to patients' unique makeup.
Becker C
Mod Healthc; 2000 Aug; 30(36):24-8, 30, 33. PubMed ID: 11186365
[TBL] [Abstract][Full Text] [Related]
16. Translating pharmacogenomics: challenges on the road to the clinic.
Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics and the future of drug therapy.
Hines RN; McCarver DG
Pediatr Clin North Am; 2006 Aug; 53(4):591-619. PubMed ID: 16872995
[TBL] [Abstract][Full Text] [Related]
18. On pharmacogenomics in pharmacy benefit management.
Russell Teagarden J; Stanek EJ
Pharmacotherapy; 2012 Feb; 32(2):103-11. PubMed ID: 22392418
[TBL] [Abstract][Full Text] [Related]
19. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis in pharmacogenomics.
Payne K; Shabaruddin FH
Pharmacogenomics; 2010 May; 11(5):643-6. PubMed ID: 20415553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
